Fresenius Medical Care North America’s (FMCNA) Renal Therapies Group announced today that DELFLEX peritoneal dialysis solutions in Biofine, an innovative bag material, has been approved by the U.S. Food and Drug Administration (FDA). The milestone marks another important step in the company’s commitment to grow home dialysis through new and improved products.
“The new Biofine peritoneal dialysis solutions line is part of our ongoing commitment to expand supply of peritoneal dialysis solutions and make home dialysis available to more patients with kidney failure,” said Mark Costanzo, President of FMCNA’s Renal Therapies Group. “We are excited to bring this innovative new product, which aims to make home treatment even easier, to market.”
